Navigation Links
GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
Date:8/27/2010

these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more e
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Study Also Show Minimal Effect on Heart Rhythm ... Changes in Schizophrenia Patients, VIENNA, Austria, ... being developed by Organon -- is effective,in treating acute manic episodes ... studies, were presented this week at,the 20th European College of Neuropsychopharmacology ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) announced today ... granted approval of IXEMPRA(TM) (ixabepilone) as,monotherapy for the ... cancer in patients whose tumors are resistant or ... also granted,approval of IXEMPRA in combination with capecitabine ...
... Senior Management Team, ROCKVILLE, Md., Oct. 16 ... pharmaceutical company developing,therapeutics for the treatment of cancer ... Ph.D. has been appointed its Senior Vice,President, Research ... an,executive officer of EntreMed by the Board of ...
Cached Biology Technology:Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 2Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 3Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 4Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 5Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 3FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 4FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 5FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 7EntreMed Appoints Senior Vice President of Research and Development 2EntreMed Appoints Senior Vice President of Research and Development 3EntreMed Appoints Senior Vice President of Research and Development 4
(Date:4/17/2014)... German . ... demanded of him, he can expect his premises to be ... of the consequences is enough to make restaurant owners pay ... lay their eggs in other birds, nests. If the host ... their revenge by destroying the entire nest. Consequently, it is ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
(Date:4/17/2014)... wild animals and plant life, but there,s an invisible ... in the soil, decomposing organic matter and releasing carbon ... fungi play in ecological systems, their identities have only ... generated a genetic map of more than 10,000 species ... this week in the Proceedings of the National ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... was until now believed that nocturnally migrating songbirds, while ... long, challenging trans-continental migrations, could at least release anti-predator ... study by Spanish and Swiss scientists ?published this week ... not without predation risk for passerines. , A ...
... be reunited with its owner than a lost cat, according to two ... that 71 percent of lost dogs were found, compared to just 53 ... recovered dogs were found by a call or visit to an animal ... wore a dog license or identification tag at the time of its ...
... mean big things for cancer patients in the future. Gary ... of Kentucky published their findings today in Nature Genetics, an ... stem cell gene and its protein product, Laxetin, and building ... to the identification of the gene itself. This is the ...
Cached Biology News:Bats prey on nocturnally migrating songbirds 2Bats prey on nocturnally migrating songbirds 3Bats prey on nocturnally migrating songbirds 4Lost dogs found more often than lost cats, study suggests 2Lost dogs found more often than lost cats, study suggests 3Researchers first to map gene that regulates adult stem cell growth 2
This depletion cocktail is tailored to deplete IgE-bearing (I.e. basophils and mast cells) from whole blood...
... gels The SpinPrep Gel DNA Kit enables efficient ... 12,000 bp in size from agarose gels. The procedure ... by adsorption of the DNA to a silica membrane ... the purified DNA is eluted in low-salt buffer. Each ...
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... This microscope is described by end-users to ... incorporates the fundamentals of light microscopy and ... small footprint, it does not require much ... a busy lab environment. The DM-BA300 combines ...
Biology Products: